Increments of α-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer

Journal of Surgical Oncology

Volumn 100, Issue 6, 2009, Pages 459-465

  Yong, Wha Moon ^a,b   Sun, Young Rha ^a,b   Xianglan, Zhang ^a   Jeung, Hei Cheul ^a,b   Woo, Ick Yang ^a   Kwon, Obin ^a   Jae, Heon Jeong ^a,b   Sung, Hah Cheon ^a   Nae, Choon Yoo ^a,b   Hyun, Cheol Chung ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Dystroglycan; Gastric carcinoma; Liver metastasis; Prognosis

Indexed keywords

ALPHA DYSTROGLYCAN; PARAFFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE INTERVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; STOMACH ADENOCARCINOMA; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; CATHETER ABLATION; DYSTROGLYCANS; FEMALE; GASTRECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH; STOMACH NEOPLASMS;

EID: 70350348728     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21347     Document Type: Article

References (23)

1. Henry MD, Campbell KP: A role for dystroglycan in basement membrane assembly. Cell 1998;95:859-870. (Pubitemid 29014465)
2. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, et al.: Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992;355:696-702.
3. Gee SH, Blacher RW, Douville PJ, et al.: Laminin-binding protein 120 from brain is closely related to the dystrophin-associated glycoprotein, dystroglycan, and binds with high affinity to the major heparin binding domain of laminin. J Biol Chem 1993;268:14972-14980. (Pubitemid 23206646)
4. Gesemann M, Brancaccio A, Schumacher B, et al.: Agrin is a highaffinity binding protein of dystroglycan in non-muscle tissue. J Biol Chem 1998;273:600-605. (Pubitemid 28042250)
5. Friedrich MV, Göhring W, Mörgelin M, et al.: Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V. J Mol Biol 1999;294:259-270.
6. Michele DE, Campbell KP: Dystrophin-glycoprotein complex: Post-translational processing and dystroglycan function. J Biol Chem 2003;278:15457-15460. (Pubitemid 36799650)
7. Ervasti JM, Ohlendieck K, Kahl SD, et al.: Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 1990;345:315-319. (Pubitemid 20159538)
8. Ohlendieck K, Matsumura K, Ionasescu VV, et al.: Duchenne muscular dystrophy: Deficiency of dystrophin-associated proteins in the sarcolemma. Neurology 1993;43:795-800. (Pubitemid 23121977)
9. Petersen OW, Rønnov-Jessen L, Howlett AR, et al.: Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 1992;89:9064-9068.
10. Singh J, Itahana Y, Knight-Krajewski S, et al.: Proteolytic enzymes and altered glycosylation modulate dystroglycan function in carcinoma cells. Cancer Res 2004;64:6152-6159. (Pubitemid 39129416)
11. Losasso C, Di Tommaso F, Sgambato A, et al.: Anomalous dystroglycan in carcinoma cell lines. FEBS Lett 2000;484:194-198. (Pubitemid 30811096)
12. Sgambato A, Di Salvatore MA, De Paola B, et al.: Analysis of dystroglycan regulation and functions in mouse mammary epithelial cells and implications for mammary tumorigenesis. J Cell Physiol 2006;207:520-529.
13. Jing J, Lien CF, Sharma S, et al.: Aberrant expression, processing and degradation of dystroglycan in squamous cell carcinomas. Eur J Cancer 2004;40:2143-2151. (Pubitemid 39165549)
14. Sgambato A, De Paola B, Migaldi M, et al.: Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J Cell Physiol 2007;213:528-539. (Pubitemid 47509736)
15. Henry MD, Cohen MB, Campbell KP: Reduced expression of dystroglycan in breast and prostate cancer. Hum Pathol 2001;32:791-795. (Pubitemid 32803978)
16. Sgambato A, Migaldi M, Montanari M, et al.: Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 2003;162:849-860. (Pubitemid 36237493)
17. Sgambato A, Tarquini E, Resci F, et al.: Aberrant expression of alpha-dystroglycan in cervical and vulvar cancer. Gynecol Oncol 2006;103:397-404. (Pubitemid 44740098)
18. Sgambato A, Camerini A, Amoroso D, et al.: Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma. Cancer Biol Ther 2007;6:1840-1846. (Pubitemid 351590394)
19. Teo K, Gemmell L, Mukherjee R, et al.: Bad expression influences time to androgen escape in prostate cancer. BJU Int 2007;100:691-696. (Pubitemid 47205461)
20. Shen X, Jin W, Cui H, et al.: Cellular adjustment of gastric cancer for hepatic metastasis in successive orthotopic implantation model. Cancer Biol Ther 2006;5:1313-1319. (Pubitemid 44772257)
21. Zung US, Lee CH, Baek SU, et al.: A multivariate analysis of prognostic factors of 3176 gastric cancers. J Korean Cancer Assoc 1994;26:179-187.
22. Yamada H, Saito F, Fukuta-Ohi H, et al.: Processing of beta-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum Mol Genet 2001;10:1563-1569. (Pubitemid 32734308)
23. Cheon SH, Rha SY, Jeung HC, et al.: Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 2008;19:1146-1153.